Key Drivers
- Strong gross-margin
- High leverage
- Solid FCF
AIAI Summary
CNMD's upside now hinges on execution and mix-shift into a few high‑margin platforms (AirSeal, Buffalo Filter, BioBrace) rather than a broad legacy recovery, meaning sustained adjusted EPS beats and demonstrable margin expansion are the specific catalysts investors should require. Key risk: persistent tariffs, the GI exit's earnings hit, or failure to materially cut net debt would likely trigger impairment and refinancing downside despite strong FCF generation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong gross-margin
- •High leverage
- •Solid FCF
CNMD generates strong revenue and gross margins with meaningful free cash flow and a dividend, but thin operating/net margins, substantial long-term debt and heavy intangibles undermine capital efficiency and leave current multiples elevated.
Price Behavior
Key Price Behavior Insights:
- •Sustained selling
- •Support turned resistance
- •Mean‑reversion possible
Over the last month the stock is in a clear downtrend—down ~20% from the mid‑$40s to $35.94, broke support near $36.70 and will likely stall at the low‑to‑mid‑$40s without strong volume or positive catalysts.
Sharp ~20% decline from mid‑$40s to $35.94 over the last month
Sentiment & News
Key News Insights:
- •Product momentum
- •Tariff headwinds
- •GI exit
Conmed surged 22.9% post-earnings as analysts recommend holding given AirSeal/Buffalo Filter/BioBrace-driven operational recovery from supply-chain normalization, offset by tariff pressures and EPS hit from a GI-business exit.
Sustained supply-chain normalization could lift key product revenues and the stock, but tariff impacts and the GI exit are likely to constrain near-term EPS and limit upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings